Amphista Therapeutics received FDA IND clearance for AMX-883, an oral BRD9 degrader for acute myeloid leukemia. The company plans to start a Phase I trial in relapsed or refractory AML and high-risk myelodysplastic syndrome in the second half of the year, with the study designed to support dose finding and early safety assessment.